Research And Development
Biotechnology
Biopharmaceutical
BioCryst
$3.409876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.22 (-6.21%) Today
+$0.08 (2.41%) After Hours
Why Robinhood?
You can buy or sell BioCryst and other stocks, options, ETFs, and crypto commission-free!
About
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. Read More The company was founded in 1986 and is headquartered in Durham, NC.
Employees
100
Headquarters
Durham, North Carolina
Founded
1986
Market Cap
366.10M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
926.76K
High Today
$3.53
Low Today
$3.29
Open Price
$3.40
Volume
3.39M
52 Week High
$9.95
52 Week Low
$3.10
Collections
Research And Development
Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Technology
US
North America
News
Seeking AlphaMay 24
BioCryst +2.4% as director buys 3,000 shares
BioCryst Pharmaceuticals (NASDAQ:BCRX) is up 2.4% in postmarket trading after an SEC filing indicating director Steve Aselage bought 3,000 shares.
Seeking AlphaMay 22
BioCryst Pharmaceuticals Is In A Very Tough Position After BCX7353 Phase 3 'Success'
The stock plunged more than 50% despite phase 3 success as the results were underwhelming and far inferior to Takeda's Takhzyro. BioCryst Pharmaceuticals (BCRX) announced that its phase 3 study of BCX7353 in HAE patients met the primary endpoint, but the stock lost more than half its value. The reason for the plunge despite the successful topline is simple – the results are deeply unsatisfying as BCX7353 has shown significantly worse efficacy than its approved competitor Takzhyro. BioCryst tried to tout so...
Price Paid on Robinhood
9% Lower
Right Now
52 Week Low
$3.10
Average Price Paid
$3.74
52 Week High
$9.95
Earnings
-$0.28
-$0.24
-$0.19
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, Pre-Market